Antigen testing for human immunodeficiency virus (HIV) and the magnet effect: Will the benefit of a new HIV test be offset by the numbers of higher-risk, test-seeking donors attracted to blood centers?

Transfusion

Volumn 36, Issue 3, 1996, Pages 203-208

  Korelitz, J J ^a   Busch, M P ^b,c   Williams, A E ^d  

^a WESTAT   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Blood Centers of the Pacific   (United States)

^d AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24;

ARTICLE; BLOOD DONOR; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; SCREENING TEST; VIRUS DETECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS SERODIAGNOSIS; BLOOD DONORS; HIV CORE PROTEIN P24; HIV-1; HUMANS; INCIDENCE; RISK FACTORS;

EID: 0029863027     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.36396182135.x     Document Type: Article

References (23)

1. Busch MP. Applications of molecular biology to infectious disease screening of blood donors. In: Allen RW, AuBuchon JP, eds. Molecular genetics in diagnosis and research. Bethesda: American Association of Blood Banks, 1995:111-38.
2. Alter HJ. To C or not to C: these are the questions. Blood 1995;85:1681-95.
3. Busch MP, Alter HJ. Will human immunodeficiency virus p24 antigen screening increase the safety of the blood supply and, if so, at what cost? (editorial). Transfusion 1995;35:536-9.
4. Center for Biologics Evaluation and Research. Recommendations for donor screening with a licensed test for HIV-1 antigen. Rockville, MD: Food and Drug Administration, August 8, 1995.
5. Busch MP, Lee LLL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995;35:91-7.
6. Dow BC, Follett EA, Munro H, et al. Failure of 2nd- and 3rd-generation HCV ELISA and RIBA to detect HCV polymerase chain reaction-positive donations (letter) Vox Sang 1994;67:236-7.
7. Jagodzinski L, Kraus F, Garrett P, et al. Detection of hepatitis B viral sequences in early HBV infection (abstract). Transfusion 1994;34(Suppl):37S.
8. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-905.
9. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis 1993;168:1343-8.
10. Rasenack JW, Schlayer HJ, Hettler F, et al. Hepatitis B virus infection without immunological markers after open-heart surgery. Lancet 1995;345:355-7.
11. Le Pont F, Costagliola D, Rouzioux C, Valleron AJ. How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests? Transfusion 1995;35:542-7.
12. Busch MP, Operskalski EA, Mosley JW, et al. Epidemiologic background and long-term course of disease in human immunodeficiency virus type 1-infected blood donors identified before routine laboratory screening. Transfusion Safety Study Group. Transfusion 1994;34:858-64.
13. Doll LS, Petersen LR, White CR, Ward JW. Human immunodeficiency virus type 1-infected blood donors: behavioral characteristics and reasons for donation. HIV Blood Donor Study Group. Transfusion 1991;31:704-9.
14. Lackritz EM, Kennedy MB, Doll LS, et al. Risk behaviors and test seeking among HIV-positive blood donors (abstract). Transfusion 1995;35(Suppl):42S.
15. Williams AE, Thomson RA, Horton JA, Kleinman SH, for the NHLBI REDS Study. Characterization of active blood donors who recently donated blood primarily to receive an HIV test (abstract). Transfusion 1995;35(Suppl):42S.
16. Busch MP. HIV and blood transfusions: focus on seroconversion. Vox Sang 1994;67(Suppl 3):13-8.
17. Petersen LR, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994;34:283-9.
18. Busch MP, Herman SA, Henrard D, et al. Time course and kinetics of HIV viremia during primary infection (abstract). Program and Abstracts from the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, February 28-March 1, 1996:60.
19. Heredia A, Guo ZP, Yu MW, et al. Detection of HIV-1 by RNA PCR in factor VIII concentrates (letter). Vox Sang 1994;67:402-3.
20. Korelitz JJ. Demographic and serologic characteristics of volunteer blood donors: the Retrovirus Epidemiology Donor Study (REDS). Presented at the Institute of Medicine Forum on Blood Safety and Blood Availability, Washington, DC, July 12-13, 1994.
21. Lackritz EM, Satten GA, Kennedy MB, et al. Residual risk of transfusion-associated HIV transmission (abstract). Program and Abstracts from the National Institutes of Health Consensus Development Conference on Infectious Disease Testing for Blood Transfusions, Bethesda, MD, January 9-11, 1995:21.
22. Busch MP, Korelitz JJ, Kleinman SH, Schreiber GB, and Retrovirus Epidemiology Donor Study. Projected yield of screening blood donors for HIV, HBV and HCV nucleic acids (abstract). Transfusion 1995;35(Suppl):39S.
23. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded HIV test protocols for donated blood (abstract). Transfusion 1995;35(Suppl):43S.